Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Xbrane Biopharma AB ( (SE:XBRANE) ) is now available.
Xbrane Biopharma AB has announced the formation of its nomination committee for the upcoming 2026 Annual General Meeting. The committee, representing approximately 26% of the company’s shares and votes, includes members appointed by the company’s three largest shareholders. The committee’s responsibilities include preparing proposals for the Chairman of the Annual General Meeting, board candidates, and compensation matters, which will be presented ahead of the meeting. This development is significant for stakeholders as it outlines the governance structure and decision-making process leading up to the AGM, potentially impacting the company’s strategic direction.
The most recent analyst rating on (SE:XBRANE) stock is a Hold with a SEK23.50 price target. To see the full list of analyst forecasts on Xbrane Biopharma AB stock, see the SE:XBRANE Stock Forecast page.
More about Xbrane Biopharma AB
Xbrane Biopharma AB is a company that develops biological drugs using a patented platform technology designed to significantly reduce production costs compared to competitors. The company has a portfolio of biosimilar candidates targeting an estimated EUR 23 billion in annual peak sales of the respective reference products. Xbrane’s lead candidate, Ximluci®, received market authorization approval in Europe and was launched in 2023. The company is headquartered in Solna, Sweden, and is listed on Nasdaq Stockholm under the ticker XBRANE.
YTD Price Performance: 15.93%
Average Trading Volume: 119,085
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK480.1M
See more data about XBRANE stock on TipRanks’ Stock Analysis page.